In this issue:
- PRL detection on 1.5T MRI in patients with MS
- aHSCT vs alemtuzumab or ocrelizumab in relapsing MS
- Age-dependent responses to high efficacy DMTs in relapsing MS
- Cognitive reserve in MS: The role of depression and fatigue
- MS relapse clinic report
- Natalizumab de-escalation strategies in Austria
- Cannabis and cognitive function in MS
- Cognitive changes in patients with MS treated with high efficacy therapies
- Influence of cortical lesions on cognitive functioning in MS
- Misdiagnosis of neurogenetic diseases as MS
Please login below to download this issue (PDF)